Johnson & Johnson Reports Five-Year CASSIOPEIA Data for Darzalex in Transplant-Eligible Myeloma

Johnson & Johnson today presented five-year follow-up data from the Phase 3 CASSIOPEIA trial evaluating Darzalex (daratumumab) plus bortezomib, thalidomide, and dexamethasone (VTd) versus VTd in patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplantation. The data showed that the progression-free survival benefit of Darzalex was maintained at five years.